Yahoo Finance Insider Sale: President and Director David Roberts Sells Shares of LeMaitre Vascular Inc (LMAT)
On May 6, 2024, David Roberts, President and Director of LeMaitre Vascular Inc (NASDAQ:LMAT), sold 5,025 shares of the company, according to a recent SEC Filing. This transaction is part of a series of sales by the insider over the past year, totaling 5,025 shares sold.
LeMaitre Vascular Inc is a global provider of medical devices for the treatment of peripheral vascular disease. The company designs, manufactures, and markets a wide range of products that provide solutions to vascular surgeons.
The shares were sold at a price of $75.62, valuing the transaction at approximately $380,065.50. Following this transaction, the market cap of LeMaitre Vascular Inc stands at $1.683 billion.
The price-earnings ratio of the company is 49.67, which is above the industry median of 30.22. This ratio is also higher than the company's historical median, indicating a premium valuation compared to its earnings.
According to the GF Value, the intrinsic value of LeMaitre Vascular Inc is estimated at $62.27 per share, making the stock modestly overvalued with a price-to-GF-Value ratio of 1.21.
Over the past year, there have been no insider buys and 14 insider sells at LeMaitre Vascular Inc, indicating a trend of insider sales.
This insider activity and the current valuation metrics provide investors with critical data points for monitoring LeMaitre Vascular Inc's stock performance and insider sentiment.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
This article first appeared on GuruFocus.
